Dyno Therapeutics

Dyno Therapeutics is a biotech startup that is revolutionizing the gene therapy landscape through the use of Artificial Intelligence (AI). The company specializes in the creation of Adeno-associated virus (AAV) vectors, which are tools used in gene therapy to deliver genetic material into cells. Dyno's AI-powered technology allows for the creation of optimized AAV vectors, which have the potential to improve the effectiveness of gene therapies.

The company operates in the biotech and healthcare market, serving pharmaceutical and biotech companies that are developing gene therapies. Notable clients include Astellas, Roche, Sarepta, and Novartis, with whom Dyno collaborates to develop improved gene therapies for various diseases, including those affecting the skeletal and cardiac muscles, the central nervous system (CNS), liver, and eyes.

Dyno's business model revolves around its proprietary AI technology, which it uses to design and optimize AAV vectors. The company generates revenue through partnerships with pharmaceutical and biotech companies, who use Dyno's AAV vectors in their gene therapy research and development.

The company has been recognized for its innovative work, being named one of the most promising startups of 2021 by Endpoints News, and Emerging Company of the Year by the New England Venture Capital Association. It has also been listed on Forbes' list of America's Best Startup Employers for two consecutive years.

Keywords: Biotech, Gene Therapy, Artificial Intelligence, AAV Vectors, Pharmaceutical Partnerships, Healthcare, CNS Gene Delivery, Skeletal and Cardiac Muscle Diseases, Ocular Diseases, Liver Diseases.